Proudly presenting the new concept fighting cervical cancer in Spain:
Self-sampling by XytoTest - HPV Hr-DNA by Abbott and risk stratification by PreTect HPV-Proofer.
An unique combination!
"Mía by XytoTest®, a preventive comprehensive diagnostic system has completed its integration in Spain to prevent cervical cancer.
Our preventive protocol offers a unique sample collection technique ensuring sufficient amount and quality of cervical/vaginal specimens for HPV- testing. These samples will be analyzed targeting DNA to identify HPV-Hr infections using Abbott Laboratories technology.
In addition, to those positive samples for any HPV-Hr infection, a triage process will be implemented by detecting HPV mRNA E6/E7. The triage using the same original sample will risk stratify among the infections and indicate the ones most likely to progress to severe cervical disease or cervical cancer. By identifying the few women at highest risk, follow-up and treatment can be immediately effectuated, hereby preventing cervical cancer. The triage test is the most advanced mRNA method developed, patented by PreTect AS, Norway," said Mel-Mont Medical's COO, Frank Meléndez
PreTect will be participating in the following events. Don`t hesitate to get in contact; We will be pleased to meet you!
Call: + 47 40403495 / + 47 40403494
Lisbon, 2-5 December 2018: "EUROGIN 2018, International multidisciplinary HPV congress"
Rome, 12-13 April 2018: "13th Workshop on Lower Genital Tract Pathology"
Årsmøte Norsk Forening for Klinisk Cytologi 2018, Sundvolden 25-26 januar 2018
MD. C.J. Nybø
EUROGIN 2017, Amsterdam 08-11 October 2017
"5-type HPV mRNA negative women in triage of ASC-US/LSIL may return to screening at 3-year interval - an historical prospective cohort study"
Prof. MD. F.E.Skjeldestad